Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: a randomized, equivalent trial.

To evaluate the efficacy and safety of oral magnesium supplementation, with magnesium chloride (MgCl2), in the treatment of newly diagnosed depression in the elderly with type 2 diabetes and hypomagnesemia. Twenty-three elderly patients with type 2 diabetes and hypomagnesemia were enrolled and randomly allocated to receive either 50 mL of MgCl2 5% solution equivalent to 450 mg of elemental magnesium or Imipramine 50 mg daily during 12 weeks. Widowhood or divorce in the last six months, alcoholism, degenerative illnesses of the nervous central system, recent diagnosis of diabetes, previous or current treatment with antidepressants, chronic diarrhea, use of diuretics, and reduced renal function were exclusion criteria.

Depressive symptoms and hypomagnesemia in older diabetic subjects.

Background: We undertook this study to assess the hypothesis that hypomagnesemia is associated with depressive symptoms in older people with diabetes.

Methods: A total of 55 type 2 diabetic patients, aged 65 years or older, with depressive symptoms were compared with a control group of diabetic subjects without depressive symptoms in an age- and gender-matched case/control study. A score >or=11 points in the Yesavage's scale was used for defining depressive symptoms, and hypomagnesemia was defined by serum magnesium levels <0.